Currently Browsing
Our Products
Aurobindo Receives FDA Approval for Niacin Extended-Release Tablets USP
Overview
- Reference Brand:
- Therapeutic Class:
Specifications
Order Information
Attributes
- Physical Form:
June 09, 2026 | Aurobindo Receives FDA Approval for Cephalexin For Oral Suspension USP, 125 mg/5 mL and 250 mg/5 mL ... Read more
June 03, 2026 | Aurobindo Receives FDA Approval for Tofacitinib Tablets, 5 mg and 10 mg ... Read more
June 02, 2026 | Aurobindo Receives FDA Approval for Eluxadoline Tablets, 75 mg and 100 mg ... Read more